MMS | Jotup

Maximus Reports Fiscal Year 2024 Second Quarter Results

Retrieved on:

水曜日, 5月 8, 2024

Highlights for the second quarter of fiscal year 2024 include:

Key Points:

Highlights for the second quarter of fiscal year 2024 include:
Revenue increased 11.7% to $1.35 billion, compared to $1.21 billion for the prior year period.
Revenue for the second quarter of fiscal year 2024 increased 11.7% to $1.35 billion, compared to $1.21 billion for the prior year period.
For the second quarter of fiscal year 2024, operating margin was 9.5% and the adjusted operating margin was 11.1%.
Maximus is raising fiscal year 2024 guidance following second quarter results and an improved outlook for the remainder of the fiscal year.

Companies Lag in Endpoint Management, Stratix Research Highlights Security Vulnerabilities

Retrieved on:

水曜日, 5月 8, 2024

MMS, Personal computer, Organization, Unified endpoint management, Internet of things, Partnership, Research report, Research, UEM, Managed Mobility Services

But instead of holistic Unified Endpoint Management (UEM) strategies that streamline IT tasks and secure endpoints regardless of device type, most companies are juggling between two and four endpoint management platforms.

Key Points:

But instead of holistic Unified Endpoint Management (UEM) strategies that streamline IT tasks and secure endpoints regardless of device type, most companies are juggling between two and four endpoint management platforms.
"Most companies have deployed endpoint management platforms piecemeal as they rolled out new technology," explained Stratix Senior Vice President Marketing Elizabeth Klingseisen.
Companies that move to comprehensive UEM solutions can enforce consistent security policies across all devices and provide users with similar experiences.
The research shows companies are missing significant opportunities to improve IT operations and protect themselves from cyber-attacks.

Epredia and NovaScan Announce Intent to Enter U.S. Distribution Agreement for MarginScan™ Device for Non-Melanoma Skin Cancer Detection

Retrieved on:

金曜日, 5月 3, 2024

View the full release here: https://www.businesswire.com/news/home/20240502185446/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20240502185446/en/
MarginScan™ Device for Non-Melanoma Skin Cancer Detection (Photo: Business Wire)
Skin cancer is the most common group of cancers diagnosed worldwide1, and it is estimated that one in five Americans will develop skin cancer in their lifetime2.
Non-melanoma skin cancers (NMSC) are the most common cancers in the United States, affecting more than 3 million Americans a year3.
Most surgeries for NMSC are simple excisions, which may result in removal of substantial healthy tissue around the suspected cancer.
With this planned agreement, Epredia will serve as the primary distribution partner of MarginScan™ and will have exclusive distribution rights in the United States.

RENI - Resilient Energy Inc. Announces Major Breakthrough: Recent Acquisition, Challenger Aerospace & Defense, Inc., Secures Order for Cutting-Edge Aerial Surveillance System

Retrieved on:

水曜日, 5月 1, 2024

MMS, USD, Acceleration, Aerospace, Intelligence, Government, Research report, IO, GPU, Defense, 3D printing

HOUSTON, May 1, 2024 /PRNewswire/ -- Resilient Energy, Inc. (OTC Markets: RENI) ("RENI" or "the Company") is pleased to announce an inaugural order received by its recently acquired powerhouse, Challenger Aerospace & Defense, Inc ("CADI"). RENI anticipates immediate revenues of approximately $552,000, bolstered by the received purchase orders. This milestone marks RENI's bold entry into the dynamic global airborne surveillance market, which is expected to grow to over $9.2 billion by 2033.

Key Points:

HOUSTON, May 1, 2024 /PRNewswire/ -- Resilient Energy, Inc. (OTC Markets: RENI) ("RENI" or "the Company") is pleased to announce an inaugural order received by its recently acquired powerhouse, Challenger Aerospace & Defense, Inc ("CADI").
RENI anticipates immediate revenues of approximately $552,000, bolstered by the received purchase orders.
This milestone marks RENI's bold entry into the dynamic global airborne surveillance market, which is expected to grow to over $9.2 billion by 2033.
Mr. Jon Bianco, CEO of Resilient Energy, Inc., hailed the recent influx of orders, stating, "Challenger Aerospace & Defense, Inc. sets the bar high, and we eagerly rise to the challenge.

Three-quarters of New Jerseyans Familiar With Proper Guidelines to Store and Dispose of Medications, Opioids and Edibles

Retrieved on:

木曜日, 4月 25, 2024

MMS, Education, Hispanic, Mobile, Partnership, Family, Patient, Rutgers University, Public interest, PSAS, Organization, Woman

Forty-two percent of residents polled in December say they are very familiar with the proper guidelines to store and dispose of any form of medication, opioids and/or edibles in a household, 32 percent are somewhat familiar and 23 percent aren’t familiar; 2 percent are unsure.

Key Points:

Forty-two percent of residents polled in December say they are very familiar with the proper guidelines to store and dispose of any form of medication, opioids and/or edibles in a household, 32 percent are somewhat familiar and 23 percent aren’t familiar; 2 percent are unsure.
“New Jersey is now one of the states with the lowest opioid dispensing rates in the country.”
Women claim to be slightly more familiar with storage and disposal guidelines than men.
"But the persistent misuse of opioids within our communities underscores the need to continue our education and prevention efforts.
The registered voter subsample contains 1,451 registered voters and has a margin of error of +/- 3.0 percentage points.

Augmedix Launches Industry’s First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments

Retrieved on:

水曜日, 4月 24, 2024

MMS, Patient, AI, HCA, Innovation, MD, HCA Healthcare, Workflow, Documentation, SVP, Physician, EDS, MBA, ED, SAN, Architecture

SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced the general availability of Augmedix Go for emergency departments (EDs), marking the launch of the industry’s first fully-automated, generative AI (GenAI) powered medical documentation product for EDs across the country.

Key Points:

SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced the general availability of Augmedix Go for emergency departments (EDs), marking the launch of the industry’s first fully-automated, generative AI (GenAI) powered medical documentation product for EDs across the country.
As part of the pilot, ED physicians in four HCA Healthcare hospitals utilized Augmedix Go to automate medical documentation, with the product instantaneously drafting their medical notes from patient visits.
“Using Augmedix allowed me to spend more time with my patients and less time in front of my computer.
These AI models are utilized across different specialties and sections of the note to deliver high quality medical documentation.

Maximus Schedules Fiscal 2024 Second Quarter Conference Call

Retrieved on:

木曜日, 4月 11, 2024

Software, Defense, Data Analytics, Consulting, Data Management, Professional Services, Technology, Government Technology, MMS, Webcast, Broadcasting

Maximus (NYSE: MMS), a leading provider of government services worldwide, will issue a press release with its financial results for the three and six months ended March 31, 2024, after market close on Wednesday, May 8, and will host a conference call the following day at 9:00 a.m.

Key Points:

Maximus (NYSE: MMS), a leading provider of government services worldwide, will issue a press release with its financial results for the three and six months ended March 31, 2024, after market close on Wednesday, May 8, and will host a conference call the following day at 9:00 a.m.
ET on Thursday, May 9.
Shareholders are invited to submit questions for management’s consideration by emailing [email protected] up to one hour prior to the call.
The call is open to the public and available by webcast or by phone at:
For those unable to listen to the live call, a recording of the webcast will be available on investor.maximus.com .

Mobix Labs Announces MMS Technical Sales as Manufacturer’s Rep

Retrieved on:

木曜日, 4月 11, 2024

Technology, Mobile, Wireless, 5G, Semiconductor, MMS, Upstate New York, Partnership, Growth

Mobix Labs, Inc. (Nasdaq: MOBX) (“Mobix Labs” or the “Company”), a fabless semiconductor company developing disruptive next-generation connectivity solutions for wired, wireless, 5G, military, defense, aerospace, and medical industries, today announced the addition of MMS Technical Sales, Inc. (“MMS”) as its new manufacturer’s representative for its electromagnetic filtering products in the New England and Upstate New York territories.

Key Points:

Mobix Labs, Inc. (Nasdaq: MOBX) (“Mobix Labs” or the “Company”), a fabless semiconductor company developing disruptive next-generation connectivity solutions for wired, wireless, 5G, military, defense, aerospace, and medical industries, today announced the addition of MMS Technical Sales, Inc. (“MMS”) as its new manufacturer’s representative for its electromagnetic filtering products in the New England and Upstate New York territories.
The partnership is effective immediately and marks a pivotal step in Mobix Labs’ strategy to enhance its footprint in this region.
“The MMS team brings over 46 years of industrial sales experience, along with a deep knowledge of connectivity solutions, which will accelerate our growth in the New England and Upstate New York markets,” stated Fabian Battaglia, CEO of Mobix Labs.
“MMS will be a great addition and valuable asset in broadening our reach.

Get Your Study Enrolled - Designing Your Impairment Protocol to Prevent Challenges, Upcoming Webinar Hosted by Xtalks

Retrieved on:

月曜日, 4月 22, 2024

MMS, Kidney, University, FASN, Glomerular filtration rate, UNC School of Medicine, Data analysis, MD, GFR, Doctor of Philosophy, Pharmacokinetics, Clinical pharmacology, Project management, Drug development, Associate, Division, Kidney failure, Human body

TORONTO, April 22, 2024 /PRNewswire-PRWeb/ -- As drug development progresses, regulators require clarity on how products are metabolized in the human body, and the risks associated with compounds that may linger in critical organs.

Key Points:

In this free webinar, learn how renal impairment study protocols can be improved to maximize patient enrollment.
Making informed decisions about the design of a study protocol is important, as overly complex protocols can quickly narrow the patient population.
Therefore, making informed decisions about the design of a study protocol is important, as overly complex protocols can quickly narrow the patient population.
Register for this webinar to understand how impairment study protocols can be improved to maximize patient enrollment.

CallTower Revolutionizes Communication with CT Text in Webex Calling

Retrieved on:

水曜日, 4月 3, 2024

Communication, MMS, SMS, Cisco, Mobile, Mobile phone

CallTower’s Cisco Webex solution with CT Text delivers both MMS and SMS capabilities translated in over 60 languages ensuring ease of contact and conversation searching within the Webex client and simplifying communications.

Key Points:

CallTower’s Cisco Webex solution with CT Text delivers both MMS and SMS capabilities translated in over 60 languages ensuring ease of contact and conversation searching within the Webex client and simplifying communications.
Utilizing the same number used for voice calls, CT Text maximizes reach and impact of SMS and MMS users within Webex by Cisco by enabling individuals to text directly from their voice number or a group shared phone number.
CT Text further enhances global communication strategies with features like group texting and text translation for over 60 languages.
Customers can be confident that CallTower supports a wide range of Webex deployments, including basic calling scenarios, enterprise-scale Webex Calling , Webex Dedicated Instance migrations, and demanding high-volume Webex Contact Center deployments.